Comparing Secukinumab and Tofacitinib for Treating Moderate to Severe Hidradenitis Suppurativa in Adults

What this Trial Is About

Researchers are evaluating and comparing the effectiveness and safety of two treatments, secukinumab and tofacitinib, in adults with moderate to severe hidradenitis suppurativa HS. The study aims to find out which treatment works better for this condition and to understand the medical problems participants may experience with each drug. Participants will be adults aged 18 to 75 years with moderate to severe HS, specifically Hurley stage II or III, who have had an inadequate response or intolerance to previous antibiotic treatments. Participants will be randomly assigned to one of two groups. One group will receive secukinumab 300 mg by injection every week for the first month and then every four weeks for up to one year. The other group will take a daily 11 mg tablet of tofacitinib for one year. During the study, participants will visit the clinic every two weeks for the first month and then every four weeks for checkups and tests. Throughout the trial, participants will keep a diary to track their symptoms. Researchers will assess clinical response using the Hidradenitis Suppurativa Clinical Response HiSCR at 12 weeks and again at one year. They will also monitor the frequency and severity of any adverse events during the study. Safety and effectiveness will be evaluated over the full one-year treatment period, with regular laboratory tests and follow-up visits to ensure participant well-being.

A Randomized Trial Comparing the Efficacy and Safety of Secukinumab with Tofacitinib in the Treatment of Moderate to Severe Hidradenitis Suppurativa in Chinese Patients